Intech Investment Management LLC Purchases New Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Intech Investment Management LLC acquired a new stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 14,628 shares of the biotechnology company’s stock, valued at approximately $79,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its stake in shares of Aldeyra Therapeutics by 7.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 3,446 shares during the last quarter. SG Americas Securities LLC bought a new stake in Aldeyra Therapeutics in the second quarter worth $38,000. Diversified Trust Co acquired a new position in Aldeyra Therapeutics during the second quarter worth $41,000. Hennion & Walsh Asset Management Inc. raised its holdings in Aldeyra Therapeutics by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 88,122 shares of the biotechnology company’s stock valued at $292,000 after buying an additional 6,944 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Aldeyra Therapeutics by 21.7% in the second quarter. Bank of New York Mellon Corp now owns 195,722 shares of the biotechnology company’s stock worth $648,000 after buying an additional 34,885 shares during the last quarter. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Trading Up 5.5 %

Shares of NASDAQ ALDX opened at $5.22 on Monday. The business’s 50-day simple moving average is $5.17 and its 200-day simple moving average is $4.69. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. Aldeyra Therapeutics, Inc has a 52 week low of $2.71 and a 52 week high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.25). On average, analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.